Lineage Cell Therapeutics
LCTX | AMEX
$0.80
-$0.11 (-12.53%)
At close: Nov 16, 2026, 4:00 PM ET
$0.86
+$0.06 (+7.50%)
After-hours:
Nov 16, 2026, 7:48 PM ET
-12.53%
(1D)No price chart data available for 1D timeframe.
Rating
66
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #83/1021 (Top 8%)
Key Statistics
Market Data
Market Cap $201.12M
1D Range
0.77 0.95
52W Range
0.77 1.96
Valuation (TTM)
PE 33.47
PB 3.05
EV/EBITDA -73.27
Valuation (NTM)
Forward PE N/A
Forward PEG -1.71
Price Target $4.00
Cash Flow
FCF Yield -12.9%
SBC Adj. FCF Yield -15.7%
SBC Impact -21.4%
Margins
Gross Margin 95.9%
Operating Margin -280.3%
FCF Margin -240.0%
Growth (CAGR)
Revenue 3Y | 5Y 7.3% |
28.4%
Dil EPS 3Y | 5Y 53.4% |
31.3%
FCF 3Y | 5Y -6.3% |
-24.0%
Returns
ROA 1.8%
ROE 3.1%
ROIC 21.0%
Financial Health
Net Cash
$43.15M
Current Ratio 5.96
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company...
Sector Healthcare
Industry Biotechnology
Employees 75
IPO Date Mar 5, 1992
Website www.lineagecell.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.03
Miss -5.01%
YoY:
+76.92% REV
$1.43M
Miss -38.14%
YoY:
-61.04%Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$4.00
Upside
+400.00%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove LCTX